The supplemental biologics license application for Dupixent for the treatment of bullous pemphigoid in adults has been ...

Net product sales of CAPLYTA were $680.5 million for the full year 2024. This represents an increase of 47% compared to 2023.

Paris: Sanofi and CD&R have announced that they have signed the share purchase agreement in relation to the sale of a 50 ...

Over 30% of Arizona's population struggles to find a meal every day, three times a day. Fortunately, there is help. Here's where to get food assistance.

Retirement and spousal benefits are available to individuals aged 61 years and 9 months or older, who can start receiving ...

Jan. 3, 2023: The state Gaming Facility Location Board, which oversees the siting process for new casinos in the state, ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...

Beacon Hill Roll Call records local senator’s votes on roll calls from the week of Feb. 10-14. There were no roll Calls in the House last week.

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

Referees will not be required to submit any documents, but will each be sent a link to the online reference form ... If your USES application meets the minimum requirements to be considered for USES, ...

D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential. Click here to find out why I rate ...